(Q44357525)

2 December 2017

title

Disruption and potentiation of latent inhibition by risperidone: the latent inhibition model of atypical antipsychotic action (English)

1 reference

2 December 2017

1 reference

Inna Gaisler-Salomon

3

0 references

Daniela Schiller

object named as

Daniela Schiller

series ordinal

2

0 references

author name string

Ina Weiner

series ordinal

1

1 reference

2 December 2017

language of work or name

English

0 references

publication date

23 September 2002

1 reference

2 December 2017

published in

Neuropsychopharmacology

1 reference

2 December 2017

volume

28

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

499-509

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300069

2 December 2017

exact match

0 references

cites work

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

The effects of electrolytic median raphe lesions on two measures of latent inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

The effects of ritanserin, RU 24969 and 8-OH-DPAT on latent inhibition in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

5,7-Dihydroxytryptamine lesions in the fornix-fimbria attenuate latent inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Haloperidol enhancement of latent inhibition: Relation to therapeutic action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Restoration of latent inhibition by olanzapine but not haloperidol in entorhinal cortex-lesioned rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Latent inhibition: the nucleus accumbens connection revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Modulation of latent inhibition in the rat by altered dopamine transmission in the nucleus accumbens at the time of conditioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Forebrain monoamines and associative learning: I. Latent inhibition and conditioned inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Latent inhibition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Enhancement of latent inhibition in the rat at a high dose of clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Latent inhibition and autonomic responses: a psychophysiological approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Neural substrates of latent inhibition: the switching model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

The switching model of latent inhibition: an update of neural substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Differential involvement of the shell and core subterritories of the nucleus accumbens in latent inhibition and amphetamine-induced activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Disruption of latent inhibition by acute administration of low doses of amphetamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Effects of nicotine and amphetamine on latent inhibition in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

Differential performance of acute and chronic schizophrenics in a latent inhibition task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

7 January 2021

Are high-schizotypal normal participants distractible or limited in attentional resources? A study of latent inhibition as a function of masking task load and schizotypy level.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

7 January 2021

Effects of smoking status and schizotypy on latent inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

7 January 2021

The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

7 January 2021

The pharmacology of latent inhibition as an animal model of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

7 January 2021

Clinical features of latent inhibition in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

7 January 2021

Clozapine-induced potentiation of latent inhibition is due to its action in the conditioning stage: implications for the mechanism of action of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

7 January 2021

Differential effects of lesions in medial and dorsal raphe of the rat: latent inhibition and septohippocampal serotonin levels.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

7 January 2021

Screening of antipsychotic drugs in animal models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

7 January 2021

Haloperidol enhances latent inhibition in visual tasks in healthy people

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

7 January 2021

Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region, but this lesion effect can be prevented by systemic haloperidol treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300069

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300069

1 reference

release_nhqut4b6brf55f6csajhcwb4mq

2 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nhqut4b6brf55f6csajhcwb4mq

24 November 2022

mapped directly with Wikidata item

1 reference